{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:50:38Z","timestamp":1783007438611,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T00:00:00Z","timestamp":1387238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,3]]},"abstract":"Summary<\/jats:title>90<\/jats:sup>Y<\/jats:styled-content>ttrium (90<\/jats:sup>Y<\/jats:styled-content>)\u2010I<\/jats:styled-content>britumomab\u2010T<\/jats:styled-content>iuxetan combines the targeting advantage of a monoclonal antibody with the radiosensitivity of F<\/jats:styled-content>ollicular L<\/jats:styled-content>ymphoma (FL<\/jats:styled-content>). Previous studies showed that 90Y<\/jats:styled-content>\u2010IT<\/jats:styled-content> is safe and effective in relapsed\/refractory indolent FL<\/jats:styled-content>, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of \u201cupfront\u201d single\u2010agent (90<\/jats:sup>Y<\/jats:styled-content>)\u2010I<\/jats:styled-content>britumomab\u2010T<\/jats:styled-content>iuxetan in advanced\u2010stage FL<\/jats:styled-content>. The primary objective was the incidence of responses in terms of complete (CR<\/jats:styled-content>) and partial remission (PR<\/jats:styled-content>). Fifty patients with stage II<\/jats:styled-content> \u201cbulky\u201d, III<\/jats:styled-content> or IV FL<\/jats:styled-content> received a single treatment course with (90<\/jats:sup>Y<\/jats:styled-content>)\u2010I<\/jats:styled-content>britumomab\u2010T<\/jats:styled-content>iuxetan as initial therapy. The median age was 60\u00a0years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated lactate dehydrogenase level. The overall response (ORR<\/jats:styled-content>) and CR<\/jats:styled-content> rates were 94% and 86%, respectively with a median follow\u2010up of 38\u00b78\u00a0months. The median progression\u2010free survival (PFS<\/jats:styled-content>) was not reached, whereas the 3\u2010year estimated PFS<\/jats:styled-content> and overall survival (OS<\/jats:styled-content>) rate was 63\u00b74% and 90%, respectively. Grade 3\/4 neutropenia and thrombocytopenia occurred in 30% and 26% of patients respectively; none experienced grade 3\/4 non\u2010haematological toxicity. No cases of secondary haematological malignancies were observed. (90<\/jats:sup>Y<\/jats:styled-content>)\u2010I<\/jats:styled-content>britumomab\u2010T<\/jats:styled-content>iuxetan was demonstrated to be highly effective and safe as first\u2010line treatment for advanced\u2010stage FL<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12695","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T14:06:49Z","timestamp":1387289209000},"page":"710-716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Safety and efficacy of 90<\/sup>Y<\/scp>ttrium\u2010I<\/scp>britumomab\u2010T<\/scp>iuxetan for untreated follicular lymphoma patients. An I<\/scp>talian cooperative study"],"prefix":"10.1111","volume":"164","author":[{"given":"Adalberto","family":"Ibatici","sequence":"first","affiliation":[{"name":"U.O. Ematologia 1 IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Matteo","family":"Pica","sequence":"additional","affiliation":[{"name":"U.O. Ematologia 1 IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Nati","sequence":"additional","affiliation":[{"name":"U.O. Ematologia 1 IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Ematologia 2 A.O. San Giovanni Battista Hospital and University Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[{"name":"Ematologia 2 A.O. San Giovanni Battista Hospital and University Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciochetto","sequence":"additional","affiliation":[{"name":"Ematologia 2 A.O. San Giovanni Battista Hospital and University Torino Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Petrini","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia A.O. Pisana Santa Chiara Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Galimberti","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia A.O. Pisana Santa Chiara Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ciabatti","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia A.O. Pisana Santa Chiara Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Orciuolo","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia A.O. Pisana Santa Chiara Pisa Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Cattedra di Ematologia Policlinico Sant'Orsola Malpighi Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Cascavilla","sequence":"additional","affiliation":[{"name":"Divisione di Ematologia Casa Sollievo della Sofferenza San Giovanni Rotondo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Guolo","sequence":"additional","affiliation":[{"name":"U.O. Ematologia 1 IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Fraternali Orcioni","sequence":"additional","affiliation":[{"name":"U.O. Anatomia Patologica IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo M.","family":"Carella","sequence":"additional","affiliation":[{"name":"U.O. Ematologia 1 IRCCS AOU San Martino\u2010IST Genova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.6.1424.1424"},{"key":"e_1_2_7_3_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.V116.21.6.6","article-title":"An Intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non\u2010bulky follicular lymphoma (Grades 1, 2 and 3a). A preliminary analysis","volume":"116","author":"Ardeshna K.M.","year":"2010","journal-title":"Blood"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.1.268"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403202"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds517"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.12.3275.3275"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2011.03.005"},{"key":"e_1_2_7_10_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/blood.V118.21.102.102","article-title":"Fractionated 90y ibritumomab tiuxetan (Zevalin™) radioimmunotherapy as an initial therapy of follicular lymphoma \u2010 first results from a phase II study in patients requiring treatment according to GELF\/BNLI criteria","volume":"118","author":"Illidge T.M.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830315)51:6<1083::AID-CNCR2820510619>3.0.CO;2-M"},{"key":"e_1_2_7_12_1","first-page":"433","article-title":"Is there a role for \u201cwatch and wait\u201d in follicular lymphoma in the rituximab era?","volume":"2012","author":"Kahl B.","year":"2012","journal-title":"ASH Education Program Book"},{"key":"e_1_2_7_13_1","first-page":"106","article-title":"A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma","volume":"118","author":"Kahl B.S.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041511"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V118.21.3712.3712","article-title":"Phase 1 study of radiosensitization using bortezomib in patients with relapsed non\u2010Hodgkin's lymphoma receiving radioimmunotherapy","volume":"118","author":"Kaminski M.S.","year":"2011","journal-title":"Blood"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan E.L.","year":"1958","journal-title":"Journal of American Statistical Association"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood.V91.1.331","article-title":"Lymphoma cell burden in progenitor cell grafts measured by competitive polymerase chain reaction: less than one log difference between bone marrow and peripheral blood sources","volume":"91","author":"L\u00e9onard B.M.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.6400"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.41.1553"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3793"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.076"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12695","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T14:52:17Z","timestamp":1696344737000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,17]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/bjh.12695"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12695","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,17]]},"assertion":[{"value":"2013-07-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-10-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-12-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}